GAIA BioMedicine

Focus: GAIA BioMedicine is a Japan-based biotechnology company founded in 2020 specializing in NK-like cell platform technology. The company operates as a pre-revenue biotech focused on cellular immunotherapy development.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About GAIA BioMedicine

AI assessmentNot Hiring

No open roles listed right now. Follow GAIA BioMedicine to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Gut Dysbiosis in Spinal Cord Injury Rehabilitation

Spinal Cord Injury

N/A

Clinical Trials (1)

NCT06892106Gut Dysbiosis in Spinal Cord Injury Rehabilitation

N/A

Help build intelligence for GAIA BioMedicine

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage opportunity to build foundational IP in emerging NK-like cell modality with potential for significant upside if platform validates clinically
Based in Japan with potential access to Asian development and commercialization partnerships and regulatory pathways
Ground-floor role at a 2020-founded company with opportunity to shape culture, processes, and scientific direction

Watch Out For

Zero active clinical trials and no disclosed pipeline programs indicate earliest-stage development with uncertain timelines and viability
No active job postings, no disclosed funding, and no financial data suggest minimal current hiring and unclear capitalization runway
Lack of published data, recent news, or public visibility creates significant uncertainty about technical progress and commercial likelihood

Generated by Claude from GAIA BioMedicine's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Molecular Determinants of Spinal Cord Injury Rehabilitation

Spinal Cord Injury

N/A

Clinical Trials (1)

NCT07383077Molecular Determinants of Spinal Cord Injury Rehabilitation

N/A

Phase I part

Gastric Cancer

Phase 1/2

Clinical Trials (1)

NCT05438459GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites

Phase 1/2

Biological

Cell Therapy

Phase 1/2

Clinical Trials (1)

NCT05207371Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2020

Portfolio: 4 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

2 pipeline

Marketed

Pipeline